Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts emphasized the considerable legal obstacles the ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

With a strong dividend yield of 7.48% and a history of maintaining dividend payments for 55 consecutive years, Pfizer demonstrates robust financial stability for such significant investments.

Pfizer announced last month that it was discontinuing development of its experimental weight-loss pill, danuglipron, after a trial participant experienced potential drug-induced liver injury.

Pfizer also plans to make a $100 million equity investment in the Chinese biotechnolgoy ... pharmaceutical firms looking to replenish their drug pipelines and boost their presence in the China ...